Analyst Ratings for Akebia Therapeutics (AKBA)
AKBA Rating Summary
AKBA Price Target Summary
- Highest: $6.00 (H.C. Wainwright)
- Lowest: $4.00 (Piper Sandler)
- Average: $5.00
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$5.00 (+293.7%)
* Over Last 12-Mos
Rating Score: 6.8 / 10
Percentile Rank: 74%
Rating Score: 6.8 / 10
Percentile Rank: 74%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/4/2025 | H.C. Wainwright » Updated 12/2/2025 |
Matthew Caufield | New Coverage | Buy (N/A) |
6.00 (N/A) |
3.42 (1.27) |
-62.87% | Details |
| 4/28/2025 | Leerink Partners | Roanna Ruiz | New Coverage | Outperform (N/A) |
75.00 (N/A) |
2.38 (1.27) |
-46.64% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
